Bli medlem
Bli medlem

Du är här

2016-04-04

FEI Company: FEI Partners with Five Pharmaceutical Companies, the Medical Research Council and the University of Cambridge to form Cryo-EM Research Consortium

Organizations involved in the Cambridge Pharmaceutical Cryo-EM Research Consortium will share access to cryo-electron microscopy equipment and methods and will collaborate on developing the technology to benefit pharmaceutical drug discovery research.HILLSBORO, Ore. and LONDON, April 04, 2016 (GLOBE NEWSWIRE) -- FEI
(NASDAQ:FEIC) has partnered with five pharmaceutical companies: Astex
Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Heptares Therapeutics, and
UCB; the Medical Research Council Laboratory of Molecular Biology (MRC-LMB);
and the University of Cambridge's Nanoscience Centre, to form the "Cambridge
Pharmaceutical Cryo-EM Consortium," which is the first of its kind worldwide.
As part of the three-year agreement, FEI will provide sample preparation and
data collection services on a Titan Krios(TM) cryo-transmission electron
microscope (cryo-EM) to the consortium companies for early-stage drug
discovery research.

The five companies involved in the consortium will share access to the
microscope with colleagues from the MRC-LMB and the University of Cambridge
in return for expert guidance on the use of cryo-EM technology. FEI's Titan
Krios will be installed at the Nanoscience Centre in May.

Richard Henderson, pioneer in the field of cryo-EM at MRC-LMB, states, "It is
delightful to know that the development of cryo-EM, which many people have
worked on for many years, has now reached mainstream structural biology. It
is particularly satisfying that pharmaceutical companies are keen to evaluate
the approach for drug development."

Prof. Sir Mark Welland, director of the Nanoscience Centre, said, "This is a
great opportunity for researchers across the University to access a
state-of-the-art microscope."

Cryo-EM has quickly become one of the most important techniques used by
structural biologists today to obtain molecular-scale three-dimensional (3D)
information about protein structures. When combined with traditional methods
for structure determination, such as x-ray crystallography and nuclear
magnetic resonance spectroscopy, the resulting models can reveal the
structure of complex, dynamic molecular assemblies down to the scale of
individual atoms. The consortium's Titan Krios will use the Relion software
package, developed by Sjors Scheres at MRC-LMB, to process the image data
into a visual 3D model that helps researchers see and understand the
structure and function of the protein.

"Cryo-EM 3D models allow us to see and understand the workings of
protein-based molecular machines that we could not analyze before because
they were too large and complex or were resistant to the preparations
required for other techniques," states Peter Fruhstorfer, vice president and
general manager of the Life Sciences business, FEI. "The technique was
rapidly adopted by leading academic researchers and is now finding its way
into early stage discovery and development in the pharmaceutical industry."

Fruhstorfer adds, "In addition to installing the Titan Krios cryo-EM system,
our contribution to the consortium includes providing an application
scientist that will work with the participating companies to ensure a smooth
workflow throughout, from sample preparation to data collection and data
processing, with a special focus on creating a standardized and robust
single-particle analysis workflow."

For more information about cryo-EM and the Cambridge Pharmaceutical Cryo-EM
Consortium, contactFEI at contactus@fei.com.

About FEI
FEI Company (Nasdaq:FEIC) designs, manufactures and supports a broad range of
high-performance microscopy workflow solutions that provide images and
answers at the micro-, nano- and picometer scales. Its innovation and
leadership enable customers in industry and science to increase productivity
and make breakthrough discoveries. Headquartered in Hillsboro, Ore., USA, FEI
has over 2,800 employees and sales and service operations in more than 50
countries around the world. More information can be found at: www.fei.com.

About the Cambridge University Nanoscience Centre
The Nanoscience Centre provides open access to over 300 researchers from a
variety of University Departments to the nanofabrication and characterisation
facilities housed in a combination of Clean Rooms and low noise laboratories.
The main activity in the building is making individual devices or structures
which are only a few nanometres in size and then measuring how they work.
Office space is primarily home to the Department of Engineering's Nanoscience
Group, technical and administrative staff and members of other research
groups who require long term access to facilities.www.nanoscience.cam.ac.uk

FEI Safe Harbor Statement
This news release contains forward-looking statements that include statements
regarding the performance capabilities and benefits of the Titan Krios TEM
and cryo-EM solution. Factors that could affect these forward-looking
statements include but are not limited to our ability to manufacture, ship,
deliver and install the tools, solutions or software as expected; failure of
the product or technology to perform as expected; unexpected technology
problems and challenges; changes to the technology; the inability of FEI, its
suppliers or project partners to make the technological advances required for
the technology to achieve anticipated results; and the inability of the
customer to deploy the tools or develop and deploy the expected new
applications. Please also refer to our Form 10-K, Forms 10-Q, Forms 8-K and
other filings with the U.S. Securities and Exchange Commission for additional
information on these factors and other factors that could cause actual
results to differ materially from the forward-looking statements. FEI assumes
no duty to update forward-looking statements.

For more information contact:
Sandy Fewkes (media contact)
MindWrite Communications, Inc.
+1 408 224 4024
sandy@mind-write.com

FEI
Jason Willey (investors and analysts)
Sr. Director, Investor Relations & Corporate Development
+1 503 726 2533
jason.willey@fei.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: FEI Company via Globenewswire

HUG#1999963

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.